Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Sponsor
Medical University of Graz
Study ID
NCT03087773
Phase
PHASE3
Status
Completed

Conditions

  • Acute Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 mg — DRUG
    The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
  • Placebo Oral Tablet — DRUG
    The subject will receive Placebo orally once daily for 26 weeks.

Study Details

This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.

Key Dates

Start date
May 11, 2017
Status verified
Aug 2024
Primary completion
May 3, 2022
Completion
May 17, 2022

Study Design

Enrollment
476 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Empagliflozin
    The subjects will receive Empagliflozin 10mg.
  • Placebo Comparator: Placebo Oral Tablet
    The subjects will receive placebo.

Primary Outcome Measure

Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels [ Time Frame: 26 weeks ]

Related Studies